Lobbying Information
Subject Matters
- Health
- Industry
- Intellectual Property
- International Trade
- Justice and Law Enforcement
- Research and Development
- Science and Technology
Subject Matter Details
Policies or Program
- Canadian Agency for Drugs and Technologies in Health (CADTH), including Therapeutic Reviews and the Common Drug Review as it relates to reimbursement recommendations for decision-making process and framework.
- Federal Innovation agenda. Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to ensure that innovative medicines, and our contribution to Research and Development in Canada are part of the consultation process in the development of this new innovation agenda.
- Federal Public Drug Plans, with respect to the reimbursement of drug products for the Federal plan beneficiaries
- Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.
- Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to provide industry recommendations on Canada's Biomanufacturing and Life Sciences Strategy, National Pharmacare, Intellectual property as well as pricing reforms (PMPRB)
Policies or Program, Regulation
- R&D requirements set forth through the Patent Medicines Pricing Review Board (PMPRB)
Regulation
- Patent Medicines Pricing Review Board reforms, regarding both the revised regulations and draft guidelines
- Patented Medicine Prices Review Board (PMPRB) Regulations as related to reporting requirements and pricing guidelines.
- Patented Medicines (Notice of Compliance) Regulations as it relates to regulation of intellectual property for therapeutic products. Novartis is working with our industry associations (Innovative Medicines Canada and BIOTECanada) to provide a written response to Guideline consultation process and will provide our own corporate submission.
Communication Techniques
-
Written communication
-
Oral communication
Government Institutions
-
Atlantic Canada Opportunities Agency (ACOA)
-
Canadian Heritage (PCH)
-
Finance Canada (FIN)
-
Global Affairs Canada (GAC)
-
Health Canada (HC)
-
House of Commons
-
Indigenous Services Canada (ISC)
-
Innovation, Science and Economic Development Canada (ISED)
-
Natural Resources Canada (NRCan)
-
Patented Medicine Prices Review Board (PMPRB)
-
Prime Minister's Office (PMO)
-
Treasury Board Of Canada Secretariat (TBS)
-
Veterans Affairs Canada (VAC)
In-house Corporation Details
Description of activities
Marketing & distribution of pharmaceuticals products.
Responsible officer name and position during the period of this registration
Andrea Marazzi,
Country President
Government funding
No government funding was received during the last completed financial year.
In-house Corporation Contact Information
Address:
385 Bouchard Blvd.
Dorval, QC H9S 1A9
Canada
Telephone number:
514-631-6775
Parent Company Information
- Novartis Holding AG
-
Forum 1
Novartis Campus
Basel CH-4056
Switzerland
Subsidiary Beneficiary Information
Novartis Pharmaceuticals Canada Inc. does not have any subsidiaries that could have a direct interest in the outcome of the undertaking
Lobbyists Details
Senior Officers whose lobbying activities represent less than 20% of their Duties
No lobbyists added
Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties
- Shona Kinley,
Director, Public Affairs and Government Relations (Fed-Atlantic) |
Public offices held